Aurobindo Pharma Ltd Share Beneficial Report for Investment in Future

Aurobindo Pharma has received tentative approval for Dolutegravir 50mg from US Food & Drug Administration (USFDA). Dolutegravir 50mg is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents.

This important milestone marks the first FDA approval of a generic version of Dolutegravir (DTG), an integrase strand transfer inhibitor recommended for use in treatment-naive patients by the US Centres for Disease Control and Prevention (CDC) and the World Health Organization (WHO).

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s